The Genital Warts Market is expected to grow with a CAGR of 6.8% in the forecast period of 2021 to 2028. The years considered for the study are as mentioned below.

Access Full Report @ https://www.databridgemarketresearch.com/reports/global-genital-warts-market

The global genital warts market is a highly consolidated market, which includes a specific number of key players as well as local players. The market has witnessed increased strategic developments owing to favorable market scenarios.

The major players dealing in the genital warts market are introducing a strong range of product portfolios. This helped companies to maximize sales with enhanced reprocessed services and product portfolios.

Merck Sharp & Dohme Corp., a subsidiary of Merck & Co., Inc., is the dominating player in the global genital warts market. The other key players existing in the market are Bausch Health Companies Inc., CryoSurgery, Inc., Taro Pharmaceutical Industries Ltd., Glenmark Pharmaceutical Inc., USA (a subsidiary of Glenmark Pharmaceuticals Ltd.), Edge Pharma, CryoConcepts LP, CryoIQ, GlaxoSmithKline plc, ANI Pharmaceuticals, Inc., Cassiopea, Inc., Verrica Pharmaceuticals, Novan, Inc., BioNTech S.E., Serum Institute of India Pvt. Ltd., Fotona, Orgenesis Inc., Perrigo Company plc among others.

 Merck Sharp & Dohme Corp., a subsidiary of Merck & Co., Inc.,

Merck Sharp & Dohme Corp., a subsidiary of Merck & Co., Inc., was founded in 1953 and is headquartered in New Jersey, U.S. The company is focused on inventing life, bringing forward the medicines and vaccines for the world’s challenging diseases in order to save and improve lives. The company deals in business segments such as pharmaceutical and animal health, out of which pharmaceutical is the market-focused market-focused segment.

• In June, Merck Sharp & Dohme Corp., a subsidiary of Merck & Co., Inc., had declared the U.S. FDA approval for GARDASIL9 (Human Papillomavirus 9-valent Vaccine, Recombinant) for the prevention of HPV-related cervical, vaginal, vulvar, anal, oropharyngeal, and other head and neck cancers. The FDA approval received would result in addressing the unmet clinical needs for the patients, increased distribution of the vaccine in hospitals and cancer research institutes for the rise in product sales. The company has a presence in North America, Europe, Asia Pacific, Middle East, and Africa.

GlaxoSmithKline plc

GlaxoSmithKline plc is headquartered in Brentford, the U.K. . and was founded in 1715. The company is focused to the become the best company in the field of innovation, development of drugs and vaccines that will be beneficial to both the patients and consumers. The company has business segments such as pharmaceuticals, consumer healthcare, vaccines, out of which consumer healthcare is the market-focused segment. The product category includes prescription medicines, vaccines, consumer healthcare, Viiv healthcare, and Stiefel dermatology, out of which consumer healthcare products are the market-focused category.  

• In May 2021, GlaxoSmithKline plc, Merck, Sharpe and Dohme, and Pfizer Inc. vaccines had received the approval from Centers for Disease Control and Prevention (CDC) to start distributing and providing vaccines to the citizens. The vaccine development and production would boost the immunization process among teenagers. It can deliver financial stability to GlaxoSmithKline plc, Merck, Sharpe and Dohme, and Pfizer Inc.

The company has a wide global presence across Asia, Australia, Latin America, Europe, Eastern Europe, Middle East, and Africa, and North America. The company has various subsidiaries, which are GlaxoSmith Kline Pharmaceuticals (Mumbai), Tesaro (U.S.), GlaxoSmithKline Pakistan (Pakistan), Stiefel Laboratories (U.S.), Allen & Hanburys(U.K.), among others

Bausch Health Companies Inc.

Bausch Health Companies Inc. is headquartered in Quebec, Canada, and was founded in the year 1959. The company is focused on improving people’s lives with our health care products and manufactures and markets a broad range of branded and generic pharmaceuticals, over-the-counter (OTC) products, and medical devices (contact lenses, intraocular lenses, ophthalmic surgical equipment, and aesthetic devices). The company offers a wide range of products in various categories such as eye health, dermatology, gastrointestinal, neurology, dentistry, out of which dermatology is a market-focused category.     

• In February 2020,  Bausch Health Companies Inc. and its dermatology business, Ortho Dermatologics, had launched the telemedicine platform on the dermatology.com portal, which is non-reimbursed for the cash pay prescription program in the U.S. The launch of the telemedicine platform would offer the patients an opportunity to consult with a healthcare expert regarding the recommendation of the safety and availability of the topical medications, such as SOLODYN (minocycline hydrochloride) extended-release tablets, EFUDEX (fluorouracil) topical cream, 5% and ALDARA (imiquimod) cream, 5%. It would result in timely treatment of the patients and increased awareness about the product.

The company has a wide global presence across the world in Europe, North America, Asia Pacific, Middle East, and Africa, and South America.  The subsidiaries are Salix Pharmaceuticals (U.S.), Solta Medical International Inc (U.S.), Bausch and Lomb (U.S.), Valeant Pharmaceuticals (U.S.), ICN Polfa Rzeszow (Poland), among others.